Do Patients Value Consulting A Prescribing Pharmacist?

Published Jun 17, 2012

Southampton, UK - A recent study originated by a joint partnership between the Universities of Southampton and Keele, UK has found that prescribing services provided by pharmacists are valued by respondents as an alternative to medical prescribing in primary care and therefore can help guide the delivery of greater patient-focused services and release some of the pressure on family doctor services.

The study, “Valuing the Extended Role of Prescribing Pharmacist In General Practice: Results from A Discrete Choice Experiment,” published in Value in Health, was specifically designed to examine how patients trade-off select characteristics of follow-up visits in choosing to attend either their ‘own doctor’, another ‘available doctor’ or a ‘prescribing pharmacist’ for managing existing long-term conditions. A choice experiment survey conducted on 451 patients attending five GP practices in England revealed clear preferences for consultations with either a ‘prescribing pharmacist’ or ‘own doctor’ rather than the ‘available doctor’ although ‘own doctor’, unsurprisingly, was most strongly preferred. Other factors in the consultation were also found to be important, in particular the level of attention paid by the professional to the patient’s views about medicines, and used to estimate acceptability of alternative prescribing services. Policies both to extend independent prescribing across the whole formulary by non-medical professionals and to deliver patient-focused health services motivated this investigation into patients’ direct valuation of non-medical prescribing. Dr. Karen Gerard, a senior health economist at the University of Southampton, comments, “With the ever increasing emphasis on patient-focused health services and escalating pressures on family doctor’s time, it is a welcome finding to learn that patients value and accept consultations with prescribing pharmacists at the general practice as an alternative in the long term management of health conditions.” The study was co-authored by Karen Gerard, Michela Tinelli, Sue Latter, Alison Blenkinsopp, and Alesha Smith. This study forms part of a wider evaluation of independent non-medical prescribing in England funded by the Policy Research Programme in the Department of Health. The views expressed are not necessarily those of the Department.

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health. For more information: www.ispor.org

Related Stories

New Research Collection Reveals How Artificial Intelligence Is Reshaping Health Economics

Nov 6, 2025

The PhRMA Foundation and ISPOR announced the publication of a special themed section of research papers that explores the dynamic intersection of artificial intelligence (AI) and health economics and outcomes research (HEOR).

ISPOR Announces 2025 Health Economics and Outcomes Research Award Honorees

Oct 20, 2025

ISPOR announced the recipients of its 2025 Health Economics and Outcomes Research (HEOR) Scientific and Leadership Awards. ISPOR Scientific Awards are designed to foster and recognize excellence and outstanding achievement in HEOR and its Leadership Awards recognize excellence and outstanding leadership in the field.

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×